Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by 89bio, Inc.

< Previous 1 2 Next >
89bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio Announces Closing of its Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio, Inc. Announces Upsized Pricing of $150.0 Million Public Offering of Common Stock and Pre-Funded Warrants
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio Reaches Alignment with the FDA and EMA on Phase 3 Program for Pegozafermin in Nonalcoholic Steatohepatitis (NASH); Program Initiation Planned in the First Half of 2024
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio Announces New Positive Long-Term Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH)
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio to Participate in the 6th Annual Evercore ISI HEALTHCONx Conference
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio Announces Additional Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Compensated Cirrhotic (F4) Nonalcoholic Steatohepatitis (NASH) at AASLD The Liver Meeting® 2023
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio to Participate in the H.C. Wainwright 7ᵗʰ Annual NASH Investor Conference
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio Announces U.S. FDA has Granted Breakthrough Therapy Designation for Pegozafermin in Nonalcoholic Steatohepatitis (NASH)
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio to Participate in the 2023 Cantor Global Healthcare Conference
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio Publishes Positive Results from Phase 2 ENTRIGUE Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) in Nature Medicine
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
Data from 89bio’s ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH) Published in The New England Journal of Medicine and Simultaneously Presented in a Late-breaker Session at the EASL International Liver Congress
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio Announces Late-Breaker Oral Presentation of Data from the Phase 2 ENLIVEN Study of Pegozafermin at EASL International Liver Congress 2023
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio Initiates Phase 3 ENTRUST Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG)
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio Reports First Quarter 2023 Financial Results and Provides Corporate Update
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio to Participate in Upcoming Investor Conferences
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio, Inc. Announces Upsized Pricing of $275 Million Public Offering of Common Stock
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio’s Phase 2b ENLIVEN Trial of Pegozafermin in Nonalcoholic Steatohepatitis (NASH) Achieved High Statistical Significance on Both Primary Histology Endpoints with Weekly (QW) and Every-Two-Week (Q2W) Dosing at 24 Weeks
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio Presents New Analysis of Data from Phase 2 ENTRIGUE Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) at American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback